Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of a recombinant anti-HER2 humanized monoclonal antibody versus trastuzumab with docetaxel and carboplatin as neoadjuvant therapy for HER2-positive breast cancer
CTR20190965Phase 3Completed
- Sponsor
- Shanghai Institute of Biological Products
- Start
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SIBP-01 in breast cancer, sponsored by Shanghai Institute of Biological Products. Started Jun 2019; status: completed.
02
Drugs
SIBP-01
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20190965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190965.